Australian Patent Secures TRP 8803 Platform to 2042
Filed with ASX · · 5 pages · English
• Australian patent relating to novel, precision-controlled method of administering psilocybin, psilocin and related forms to treat a range of pain disorders has been granted • Protects the core IP underpinning TRP-8803 (IV-infused psilocin) through to 2042 • Patent claims granted provide extensive protection around the use of two-phase IV dosing, time to onset of desired treatment state, control
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Quarterly Activities Report and Appendix 4C
- First TRP-8803 BED patient shows broad clinical improvement
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
- $847,186 R&D Tax Incentive received
- First BED patient completes second TRP-8803 infusion
Later from Entropy Neurodynamics
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- FY25 R&D Tax Incentive received
- TRP-8803 delivers repeatable, high-intensity effect
- TRP 8802 delivers 75% breakthrough response in IBS
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics